- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT03082430
GO PRP: Assessing the Efficacy of Intra Articular Injection of Platelets Rich Plasma for Gonarthrosis Treatment in Routine Care
Study GO-PRP: Assessing the Efficacy of Intra Articular Injection of Platelets Rich Plasma for Gonarthrosis Treatment in Routine Care
Studieoversigt
Detaljeret beskrivelse
The main objective is to get a 50% proportion of responders defined by answers "absent" or "light" in the KOOS questionnaire on questions about pain and difficulty walking on flat ground.
Secondary objectives include the safety validation of the use of PRP (prepared standardized manner by means of a given medical device) as second-line standard of care for osteoarthritis by the introduction of a systematic monitoring; and the feasibility of the health care system dedicated to the treatment of knee osteoarthritis by autologous PRP.
Furthermore, the secondary objectives are to monitor and follow the evolution of pain (VAS) and the knee function (KOOS score) at 1 month, 3 months, 6 months. Evaluation of MRI will be performed within 15 days prior (inclusion visit) injection and 6 months to assess the cartilage thickness and visualize a regenerative effect.
Undersøgelsestype
Tilmelding (Forventet)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
-
Marseille, Frankrig, 13008
- Hopital Saint Joseph
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Men and women 20 to 80 years
- Gonarthrosis diagnostic objectified by the criteria of the American College of Rheumatology
- Joint pain for more than 6 months
- Answer "moderate" to the question about pain walking on flat ground
- Answer "moderate" to the question about trouble walking on flat ground
- Osteoarthritis stage 2 or 3 on the scale of Kellgren Lawrence (objectified radiography) within 6 months previous inclusion
- Axial deformation of less than or equal to 5 ° lower limbs
- Informed consent signed by the patient
- HB> 10g / dl
- Beta-HCG negative at baseline
- Ability to perform the procedures in the follow-up (50 not walk on a flat surface and up / down stairs).
- Being affiliated to a system of health insurance
Exclusion criteria:
- Axial deformation > 5 °
- Ligamentous instability
- Significant injuries or target knee or knee surgery contralateral side in 12 months previous the inclusion visit
- Ligament reconstruction in the 12 months précédants the inclusion visit
- Need a cane or assistance to move
- BMI> 35
- Thrombocytopenia <150 G / L
- Thrombocytosis> 450 G / L
- Known thrombopathy
- Anemia HB <10g / dl
- Active infections to HIV 1 and 2, Agp24, HCV Ab, Ag and HbS AcHbc, Ac HTLV I and II, TPHA
- Chronic treatment with corticosteroids per os or older than 2 weeks
- Injection intra-articular corticosteroid of less than 2 months
- Intra-articular injection of hyaluronic acid of less than 6 months
- NSAIDs or antiplatelet agent of less than 15 days
- Inability to stop NSAIDs (including aspirin) 15 days before the injection and the week following the injection
- Fever or recent illness
- Autoimmune diseases
- Inflammatory arthritis
- Immune deficiency
- Infectious diseases
- Pregnant women
- Adults legally protected (under guardianship and trusteeship)
- People simultaneously participating in other biomedical research16. Inability
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Andet: knee osteoarthritis patients.
therapeutic management of symptomatic knee osteoarthritis (resistant to medical first-line treatment) by intra-articular injection of autologous PRP prepared in the same procedure and using a dedicated CE marked medical device and a validated and reproducible method of preparation.
|
one autologous PRP patient in this study and monitor and follow the evolution of pain and the knee function
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
to monitor and follow the evolution of pain
Tidsramme: prior,1 month, 3 months, 6 months
|
VAS to monitor and follow the evolution of pain
|
prior,1 month, 3 months, 6 months
|
|
to monitor and follow the evolution of the knee function
Tidsramme: prior,1 month, 3 months, 6 months
|
(KOOS score)
|
prior,1 month, 3 months, 6 months
|
|
Evaluation of MRI
Tidsramme: prior,1 month, 3 months, 6 months
|
Evaluation will be performed within 15 days prior (inclusion visit) injection and 6 months to assess the cartilage thickness and visualize a regenerative effect.
|
prior,1 month, 3 months, 6 months
|
Samarbejdspartnere og efterforskere
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- GO PRP
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .